Genmab — Maj 2017

[bibob]

Senatet accepterer Trumps FDA-kandidat

Trumps kandidat til posten som leder af de amerikanske lægemiddelmyndigheder, Scott Gottlieb, har fået grønt lys af Senatet, og skal nu gennemføre Trumps medicinbesparelses-agenda.

(medwatch.dk)

[Plimsoller]

Tak for link. En hurtigere behandling af ansøgninger må vel anses som positivt for Genmab i de kommende år.

[E_L]

Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody Antibody, in Participants With Relapsed or Refractory Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT03145181?term=JNJ-64007957&rank=1 T
his seems new?

[Sukkeralf]

Very nice E L - I hoped we would see this in the clinic this year Very happy for that

[Sukkeralf]

The CAR-T BCMA data looks very promissing so quite important that we get this study up and running

[KWC]

Thanks EL..

[GeorgeBest]

Så falder der vel en milepæl til Genmab når den første patienter behandles...

[GeorgeBest]

De plejer at være på 2-3 mio. USD

[E_L]

meanwhile Tecentriq phase III in advanced bladder cancer failed on overall survival.
http://www.roche.com/investors/updates/inv-update-2017-05-10.htm

[bibob]

Thank's for link E L. Very nice.

[bibob]

Link does'nt work E L. Tecentriq link.

[AaBforever]

reuters.com

(www.reuters.com)

[E_L]

sry doesnt work, google it lol, maybe Helge can delete the false attempts

[E_L]

last try as pdf : http://www.roche.com/dam/jcr:8fa0d3ca-f68d-413c-a8fa-cb94514492e6/en/med-cor-2017-05-10-e.pdf

[bibob]

Thanks. It works.

[bibob]

Ser ud til et rebound i dag.

[JohnW]

How does Tecentriq relates to Genmab? Is there a cooperation or is it competition?

[Sukkeralf]

Primarily combination with daratumumab

[Bulder]

Man skal ikke blive bekymret over at atezo ikke er voldsomt effektivt. Vi ved jo fra Limo Chen, at der skal noget CD38-pulver til for at det virker ordentligt.

[nik_hs1990]

Bliver spændende hvad de guider ud for resten af 2017, når regnskabet lander. Mon ikke os Jan har en kommentar omkring pipeline, som kan være interessant.